CONFERENCE DAY TWO - Thursday, June 13

7:00 am Check-In & Light Breakfast

7:55 am Chair’s Opening Remarks

From Small Molecules to Peptides to Biologics: Dealing with Hard-to-Drug, Dynamic, Proteins with the Structural Biology Toolbox – Case Study Presentations

8:00 am Unleashing the Potential: Cryo-Em’s Impact to Effectively Supercharge Structural Determination

Synopsis

  • Using Cryo-EM to answer different questions in drug discovery projects, exploring why and when to use cryo-EM

8:30 am Resolving Sample Bottlenecks through Advanced CryoEM Grid Hardware

Synopsis

  • Exploring cryo-em sample preparation
  • Highlighting cryo-em grids

8:45 am Application of Cryo-EM for Structure-Based Design Against Membrane Protein Targets

Synopsis

  • Rationalising drug design by harnessing the state-of-the-art techniques in structurebased drug design
  • Utilizing structures to increase understanding of the system

9:15 am Integrated Structure-Guided Drug Discovery accelerates success in early discovery research: A worked example from a challenging DNA-repair target, Artemis

  • Douglas Kitchen Research Fellow, Computer-Aided Drug Discovery, Discovery Services, CURIA

Synopsis

  • Designing a new protein construct that provided the first crystal structure of Artemis
  • Discussing a unique screening library produced novel hits to an allosteric binding site
  • Highlighting efficient SAR development was enabled by more than 80 co-crystal structures and collaborative efforts of medicinal and computational chemistry
  • Understanding without these structures key induced-fit effects could not have been predicted

9:45 am Structure-Based Vaccine & Antibody Discovery at AstraZeneca

Synopsis

  • Leveraging Cryo-EM in structure-based design of novel vaccine candidates
  • Highlighting structural determination of MoA for neutralising antibodies against respiratory viruses

10:15 am Morning Break

10:45 am Harnessing a Hybrid Approach Including X-Ray Crystallography, NMR, Cryo-EM, HDX, & Machine Learning to Accelerate the Discovery & Development of Vaccines

Synopsis

  • Combining and supporting structure-based vaccine identification, characterization and design with a combination of methods across discovery and development
  • Utilising machine learning to accelerate the identification of new vaccine using 3D protein structure information

11:15 am Driving Vaccine Design & Antibody Discovery Using Cryo-EM

  • Andrew Ward Professor - Department of Integrative Structural and Computational Biolog, The Scripps Research Institute

Synopsis

  • Illuminating the cryo-EM pipeline to evaluate polyclonal antibody responses
  • Increasing throughput of cryo-EM sample evaluation
  • Sequencing antibodies directly from cryoEM data and highlighting epitope mapping

11:45 am Capitalizing on Structure Biology to Target the Oncogenic State of RAS Mutants with RAS(ON) Tri-Complex Inhibitors

  • Jason Yano Director & Head of Structural Biology, Revolution Medicines

Synopsis

  • Exploring the rational design of a natural product-inspired small molecule created a neomorphic surface on an intracellular chaperone cyclophilin A that was exploited to target active KRASG12C with high affinity and selectivity
  • Harnessing further structure-guided optimization to design a novel, non-covalent compound with broad activity across the active state of multiple oncogenic (H/K/N) RAS variants
  • Showcasing the preclinical data to demonstrate the Tri-complex inhibitors selectively target active KRASG12C or multiple RAS mutants and are now in clinical trials

12:15 pm Lunch & Networking

1:45 pm Illuminating a Structural Engineering-Based Approach for Interrogating NUAK1 Kinase Selective Inhibitors

  • Silvia Delker Principal Scientist & Project Manager - Structural Biology, UCB

Synopsis

  • Designing a dynamic human NUAK1-MARK3 crystallographic chimera
  • Exploring a robust crystallizable construct, navigating SAR

1:45 pm Structure Empowered IMAPCT Platform in the Discovery & Development of Immunoglobulin Sculpting (IgSc) Enzyme & Dual-Cell Bidirectional (DcB) Antibody Drugs for Immunological Diseases

  • Yi Xing Senior Director, Seismic Therapeutics

Synopsis

  • Understanding the structural biology function and IMPACT platform
  • Exploring how structure-based rational design and machine learning design fueled drug discovery and development of IgSc enzyme
  • DcB antibody-antigen structures supporting the development of biologic drugs

Overcoming Structural Complexity in Drug Delivery & Formulation Development

2:15 pm Molecular Understanding of Drug Delivery and Stability From Solution and Solid-State NMR Spectroscopy

Synopsis

  • Utilizing real-world examples to highlight structural challenges encountered in drug development
  • Employing molecular insights from NMR to enhance drug design, focusing on improving delivery and stability
  • Appreciating interdisciplinary learning and collaboration between structural biophysics and pharmaceutical sciences

Emerging Technologies in Structure-Based Drug Design: Shaping the Future of Protein Structure Determination

3:15 pm Advancing the Development & Applications of Time-Resolved Cryo-EM

Synopsis

  • Understanding the importance and specific challenges posed by conformational dynamics to rational drug discovery
  • Exploring the development of time-resolved sample preparation for cryo-EM and single particle analysis to address these challenges
  • Discussing relevant areas of application

3:45 pm Afternoon Break

3:45 pm Enabling In-Cell Structural Biology by Large-Scale Site-Specific Photo- Crosslinking

Synopsis

  • In-cell photocrosslinking to map direct protein-protein contacts at single residue resolution
  • Photocrosslinking to unravel the architecture of GR-Hsp90-cochaperone complexes
  • Applications to functional studies and pharmacology

4:15 pm Panel Discussion: Looking to the Future of Structure-Based Drug Design: Driving Resolution & Speed

Synopsis

  • Exploring recent advancements in Cryo-EM, AI prediction, and more to push the resolution boundaries
  • Maximising integrating approaches for enhanced resolution and functional insights
  • Exploring the potential of cloud computing and collaborative platforms to make SBDD accessible and facilitate drug development
  • Delving into the practicalities of incorporating AI and machine learning
  • Assessing structure-based drug design as a continuous feedback loop to inform structure-based optimization

4:45 pm Chair’s Closing Remarks